Group 1 - Inspire Medical Systems, Inc. (NYSE:INSP) is facing challenges due to the impact of GLP-1 medications, which are affecting the company's market outlook and earnings forecast [1] - Management claims that GLP-1s will ultimately expand their total adjustable market by aiding weight loss in obese individuals, but skepticism exists regarding this argument [1] - The company has reduced its earnings forecast by nearly 80%, raising concerns about its financial health and future performance [1] Group 2 - Inspire Medical Systems specializes in developing and marketing minimally invasive therapies for obstructive sleep apnea [2] - There is a belief that certain AI stocks may present better investment opportunities with higher upside potential and lower downside risk compared to Inspire Medical Systems [3]